CATO SMS is a global provider of specialized clinical research solutions that advance drug development for small and emerging biopharmaceutical companies. The company offers a comprehensive portfolio of solutions, including product development consulting, biostatistical services and clinical trial operations. CATO SMS stands out for its strength in supporting development in complex therapeutic areas, including oncology, rare and orphan indications, and cell and gene therapy. The company was formed in 2019 when Cato Research merged with SMS-oncology. Working with Water Street, CATO SMS has completed additional strategic acquisitions and organic initiatives to deepen its oncology and regulatory expertise, expand its suite of solutions and broaden its global network.